[Daewoong Pharmaceutical Nabota] Expanding to 5th indication for Botulinum toxin
[Daewoong Pharmaceutical Nabota] Expanding to 5th indication for Botulinum toxin
  • Kim Sun, Reporter
  • 승인 2022.05.18 09:45
  • 수정 2022.05.18 09:45
  • 댓글 0
이 기사를 공유합니다

Glabellar line, upper extremity muscle stiffness after stroke, wrinkle around the eyes, eyelid spasm → addition of square jaw
[Courtesy of Daewoong Pharmaceutical]
[Courtesy of Daewoong Pharmaceutical]

‘Nabota’, a botulinum toxin developed independently by Daewoong Pharmaceutical, is striding towards its fifth indication. Currently, ‘Nabota’ has 4 indications in the cosmetic area including glabellar line, upper extremity muscle stiffness after stroke, wrinkle around the eyes and eyelid spasm.

The fifth indication that Daewoong is expanding to this time is the ‘square jaw (benign masseteric hypertrophy).

Previously, Daewoong Pharmaceutical submitted an application for new drug indication approval (NDA) to the Ministry of Food and Drug Safety in April.

‘Nabota’ is undergoing phase 2 clinical trials for cervical dystonia, and chronic and episodic migraine through U.S. partner Ion Biopharma upon approval by the U.S. Food and Drug Administration (FDA).

In 2020, as ‘Nabota’ was clinically proven to be effective in the treatment of male pattern hair loss, it was published in the December issue of Journal of the American Academy of Dermatology (JAAD), an SCI journal.

Following the square jaw, there is a possibility that 'Nabota' expands to more than 8 indications in total at present, including cervical dystonia, chronic and episodic migraines, and male pattern hair loss.

The fifth indication was based on the results of a phase 3 clinical trial conducted on 180 adults who needed improvement in the square jaw. The clinical trial was conducted in a double-blind method, in which efficacy and safety were assessed every 4 weeks for a total of 24 weeks after a single dose of Nabota or placebo was administered in a random allocation.

The results confirmed that the average change in the thickness of both masseteric masses at the maximum occlusion at 12 weeks after administration, the main endpoint, decreased by more than 20% compared to the baseline, which was a decrease of more than 7 times compared to the placebo group.

Also, in the extension study to verify the effectiveness of repeated administration, it was confirmed that the effect increased compared to the first administration in the average change in the thickness of both masseteric masses at the maximum occlusion at 12 weeks after repeated administration.

The global botulinum toxin market has a market size of over $5 billion as of 2020, and is expected to grow to more than $6 billion in 2023. Subsequently, the market for toxin treatment of the square jaw is also expected to grow.

As of the first quarter of this year, the sales of Nabota were recorded at 30.7 billion won, a 98% increase from 15.4 billion won year-to-year. Exports rose by 189% from 7.9 billion won to 22.8 billion won in the same period of last year.

An official from Daewoong Pharmaceutical said, “We submitted an application for biologics license to the Chinese National Drug Administration at the end of last year and are expecting to obtain approval within 2022 at the earliest.”

[WIKI KOREA=Kim Sun, Reporter]

kej5081@wikileaks-kr.org

기자가 쓴 기사

  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2024 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 : laputa813@wikileaks-kr.org
ND소프트